Common filaggrin gene mutations and risk of cervical cancer

Acta Oncologica

Volumn 54, Issue 2, 2015, Pages 217-223

  Bager, Peter ^a   Wohlfahrt, Jan ^a   Sørensen, Erik ^b   Ullum, Henrik ^b   Høgdall, Claus Kim ^b   Palle, Connie ^c   Husemoen, Lise Lotte Nystrup ^d   Linneberg, Allan ^d,e,f   Kjær, Susanne K ^b,g   Melbye, Mads ^a   Thyssen, Jacob P ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Research Centre for Prevention and Health   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^g DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FILAGGRIN; INTERMEDIATE FILAMENT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HAZARD RATIO; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; UTERINE CERVIX CANCER; AGED; CASE CONTROL STUDY; DENMARK; EPIDEMIOLOGY; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; REGRESSION ANALYSIS; RISK; UTERINE CERVIX TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; FEMALE; HETEROZYGOTE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MIDDLE AGED; MUTATION; ODDS RATIO; REGRESSION ANALYSIS; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 84921756294     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.973613     Document Type: Article

References (44)

1. Brown SJ, McLean WH. O ne remarkable molecule: Filaggrin. J Invest Dermatol 2012;132:751-62.
2. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-6.
3. Smith F J, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006;38:337-42.
4. O'Regan GM, Sandilands A, McLean WH, Irvine A D. Filaggrin in atopic dermatitis. J Allergy Clin Immunol 2008;122:689-93.
5. Rodriguez E, Baurecht H, Herberich E, Wagenpfeil S, Brown SJ, Cordell HJ, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease. J Allergy Clin Immunol 2009;123:1361-70.
6. Cintorino M, Syrjanen S, Leoncini P, Bellizzi De ME, Petracca R, Pallini V, et al. Altered expression of filaggrin in human papillomavirus (HPV) lesions of the uterine cervix. Arch Gynecol Obstet 1988;241:235-47.
7. Lara C, Serra V, Marzo C, Valcuende F, Castells A, Bonilla-Musoles FM. Immunohistochemical localization of filaggrin in benign, premalignant and malignant cervical tissue. Arch Gynecol Obstet 1994;255:73-9.
8. McGlennen RC, Ostrow RS, Carson LF, Stanley MS, Faras AJ. Expression of cytokine receptors and markers of differentiation in human papillomavirus-infected cervical tissues. Am J Obstet Gynecol 1991;165:696-705.
9. Kanitakis J, Ramirez-Bosca A, Reano A, Viac J, Roche P, Thivolet J. Filaggrin expression in normal and pathological skin. A marker of keratinocyte differentiation. Virchows Arch A Pathol Anat Histopathol 1988;412:375-82.
10. Viac J, Guerin-Reverchon I, Chignol MC, Chardonnet Y. Filaggrin expression in cutaneous and mucosal human papillomavirus induced lesions. Pathol Res Pract 1989;185:342-6.
11. Vigneswaran N, Peters K P, Hornstein O P, Haneke E. Comparison of cytokeratin, filaggrin and involucrin profiles in oral leukoplakias and squamous carcinomas. J Oral Pathol Med 1989;18:377-90.
12. Guerin-Reverchon I, Chardonnet Y, Viac J, Chouvet B, Chignol MC, Thivolet J. Human papillomavirus infection and filaggrin expression in paraffin-embedded biopsy specimens of extragenital Bowen ' s disease and genital bowenoid papulosis. J Cancer Res Clin Oncol 1990;116:295-300.
13. Campos AC, Murta EF, Michelin MA, Reis C. Evaluation of cytokines in endocervical secretion and vaginal pH from women with bacterial vaginosis or human papillomavirus. ISRN Obstet Gynecol 2012;2012:342075.
14. Clarke MA, Rodriguez A C, Gage JC, Herrero R, Hildesheim A, Wacholder S, et al. A large, population-based study of agerelated associations between vaginal pH and human papillomavirus infection. BMC Infect Dis 2012;12:33.
15. Gillet E, Meys JF, Verstraelen H, Bosire C, De SP, Temmerman M, et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: A meta-analysis. BMC Infect Dis 2011;11:10.
16. Currie JM, Wright RC, Miller OG. The frequency of warts in atopic patients. Cutis 1971;8:243-5.
17. Rubben A, Kalka K, Spelten B, Grussendorf-Conen EI. Clinical features and age distribution of patients with HPV 2/27/57-induced common warts. Arch Dermatol Res 1997 ; 289:337-40.
18. Rystedt I, Strannegard I L, Strannegard O. Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol 1986;114:575-82.
19. Cai SC, Chen H, Koh WP, Common JE, Van Bever HP, McLean WH, et al. Filaggrin mutations are associated with recurrent skin infection in Singaporean Chinese patients with atopic dermatitis. Br J Dermatol 2012;166:200-3.
20. Gao PS, Rafaels NM, Hand T, Murray T, Boguniewicz M, Hata T, et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 2009;124:507-13, 513.
21. Montgomery S M, Ehlin AG, Sparen P, Bjorksten B, Ekbom A. Childhood indicators of susceptibility to subsequent cervical cancer. Br J Cancer 2002;87:989-93.
22. Pedersen C B, Gotzsche H, Moller J O, Mortensen P B. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441-9.
23. Andersen T F, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8.
24. Storm H H, Michelsen E V, Clemmensen I H, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997;44:535-9.
25. Gjerstorff M L. The Danish Cancer Registry. Scand J Public Health 2011;39:42-5.
26. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39:26-9.
27. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010;268:296-308.
28. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: Baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003;10:377-86.
29. Thuesen BH, Cerqueira C, Aadahl M, Ebstrup JF, Toft U, Thyssen JP, et al. Cohort profile: The Health2006 cohort, Research Centre for Prevention and Health. Int J Epidemiol 2014;43:568-75.
30. Alleman B W, Myking S, Ryckman KK, Myhre R, Feingold E, Feenstra B, et al. No observed association for mitochondrial SNPs with preterm delivery and related outcomes. Pediatr Res 2012;72:539-44.
31. Myking S, Boyd H A, Myhre R, Feenstra B, Jugessur A, Devold Pay AS, et al. X-chromosomal maternal and fetal SNPs and the risk of spontaneous preterm delivery in a Danish/Norwegian genome-wide association study. PLoS One 2013;8:e61781.
32. Osler M, Linneberg A, Glumer C, Jorgensen T. The cohorts at the Research Centre for Prevention and Health, formerly 'The Glostrup Population Studies'. Int J Epidemiol 2011; 40:602-10.
33. Andersen AM, Olsen J. The Danish National Birth Cohort: Selected scientific contributions within perinatal epidemiology and future perspectives. Scand J Public Health 2011 ; 39:115-20.
34. Meldgaard M, Szecsi PB, Carlsen BC, Thyssen JP, Johansen JD, Menne T, et al. A novel multiplex analysis of filaggrin polymorphisms: A universally applicable method for genotyping. Clin Chim Acta 2012;413:1488-92.
35. Kjaer SK, van den Brule A J, Paull G, Svare EI, Sherman ME, Thomsen BL, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. BMJ 2002;325:572.
36. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J Natl Cancer Inst 2010;102:1478-88.
37. Koshiol J, Lindsay L, Pimenta J M, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am J Epidemiol 2008;168:123-37.
38. Gosvig CF, Huusom LD, Andersen KK, Iftner A, Cederkvist L, Svare E, et al. Persistence and reappearance of high-risk human papillomavirus after conization. Gynecol Oncol 2013;131:661-6.
39. Badaracco G, Savarese A, Micheli A, Rizzo C, Paolini F, Carosi M, et al. Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer. Oncol Rep 2010;23:1093-9.
40. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103:1387-96.
41. Skaaby T, Husemoen LL, Jorgensen T, Johansen JD, Menne T, Szecsi PB, et al. Associations of filaggrin gene loss-of-function variants and human papillomavirus-related cancer and pre-cancer in Danish adults. PLoS One 2014;9:e99437.
42. Thyssen JP, Linneberg A, Johansen JD, Carlsen BC, Zachariae C, Meldgaard M, et al. Atopic diseases by filaggrin mutations and birth year. Allergy 2012;67:705-8.
43. Chen H, Common JE, Haines RL, Balakrishnan A, Brown SJ, Goh CS, et al. Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. Br J Dermatol 2011;165:106-14.
44. U.S. Department of Health and Human Services PHSNIoH. SEER Program: Comparative staging guide for cancer. Cancer Statistics Branch, Division of Cancer Prevention and Control, National Cancer Institute 1993;NIH Publication No. 93-3640.